The founder and former CEO of several pharmaceutical companies, Tidmarsh was tapped by FDA Commissioner Marty Makary, MD, MPH ...

Pfizer Inc (NYSE:PFE) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Josh Brown, CEO of Ritholtz Wealth ...

I can’t ask you to do that because we are still on the verge of finding out what the Seagen acquisition does. Let’s give Dr.

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' Piqray/Vijoice (alpelisib) and Roche's Itovebi (inavolisib), which are currently ...

Kings Pharmaceuticals, a subsidiary of Pfizer, has voluntarily recalled select batches of Bicillin L-A over the discovery of “particulates” in the injectable solution that pose a “significant risk” an ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Celcuity shares soar 186% after Phase 3 breast cancer trial shows triple therapy delays disease by over 7 months.

The trade deal between the U.S. and the European Union could hit the pharmaceutical industry with billions in new costs and ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...